Mainz, December 20, 2018 – TRON is delighted to announce an article published in Nature.
Working with GAPVAC (Glioma Actively Personalized Vaccine Consortium), TRON participated in developing a highly personalized approach to the treatment of glioblastoma. The consortium publish data on the results of a phase 1 multi-center, multi-national clinical trial, showing favorable safety and immune response results.
Read more about the trial here.
Read more about GAPVAC here.
